Will Proteostasis Therapeutics, Inc. (PTI) Short Squeeze Soon?

June 7, 2018 - By Marie Mckinney

Proteostasis Therapeutics, Inc. (NASDAQ:PTI) Logo

The stock of Proteostasis Therapeutics, Inc. (NASDAQ:PTI) is a huge mover today! The stock decreased 38.16% or $1.87 during the last trading session, reaching $3.03. About 6.23 million shares traded or 201.78% up from the average. Proteostasis Therapeutics, Inc. (NASDAQ:PTI) has risen 10.56% since June 8, 2017 and is uptrending. It has underperformed by 2.01% the S&P500.
The move comes after 5 months negative chart setup for the $109.33 million company. It was reported on Jun, 8 by Barchart.com. We have $2.88 PT which if reached, will make NASDAQ:PTI worth $5.47M less.

More notable recent Proteostasis Therapeutics, Inc. (NASDAQ:PTI) news were published by: Benzinga.com which released: “8 Biggest Price Target Changes For Thursday” on June 07, 2018, also Benzinga.com with their article: “27 Stocks Moving In Thursday’s Pre-Market Session” published on June 07, 2018, Nasdaq.com published: “Mid-Morning Market Update: Markets Mostly Higher; JM Smucker Misses Q4 Expectations” on June 07, 2018. More interesting news about Proteostasis Therapeutics, Inc. (NASDAQ:PTI) were released by: Streetinsider.com and their article: “Pre-Open Movers 06/07: (AVHI) (CONN) (FIVE) Higher; (MDXG) (PTI) (REVG) Lower (more…)” published on June 07, 2018 as well as Prnewswire.com‘s news article titled: “Proteostasis Announces Positive Data from Ongoing Phase 1 Study of PTI-801 in Cystic Fibrosis Patients on …” with publication date: June 06, 2018.

Proteostasis Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics that treat diseases caused by dysfunctional protein processing, such as cystic fibrosis. The company has market cap of $109.33 million. The Company’s lead product candidate is PTI-428, an orally bioavailable cystic fibrosis transmembrane conductance regulator modulator belonging to the amplifier class that is in Phase-I studies. It currently has negative earnings. The firm is also developing PTI-801, a corrector molecule; PTI-808, a potentiator molecule; and unfolded protein response modulators that are in preclinical development.

Proteostasis Therapeutics, Inc. (NASDAQ:PTI) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.